NASDAQ$PRTA
Prothena Corporation plc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter of 2024 and provided business highlights.
Prothena reported a net loss of $72.2 million for the first quarter of 2024, with total revenue of $0.1 million. The company's cash and restricted cash position at the end of the quarter was $548.7 million. The company continues to advance its pipeline of investigational therapeutics.
- Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million.
- Advanced potential best-in-class Alzheimer’s disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012; received FDA clearance for IND application and Fast Track designation for PRX123; Phase 2 clinical trial initiated for BMS-986446 by partner Bristol Myers Squibb.
- Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab; published birtamimab mechanism of action and pharmacological characteristics in Leukemia & Lymphoma in April 2024.
- Daniel G. Welch appointed to Prothena Board of Directors as an independent director and Chair Designate
Headline financials
Revenue & EPS history
Prothena · Revenue · Quarterly
$50K
Revenue by segment
Prothena · $84.9M total across 1 segment · Q3 2023
- Collaboration Revenue$84.9M+5557.7%100.0%
Forward guidance
The Company continues to expect the full year 2024 net cash used in operating and investing activities to be $208 to $225 million and expects to end the year with approximately $405 million in cash, cash equivalents and restricted cash (midpoint).
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.5%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+0.2%
Avg return
30 days after
57%
30 / 53 earnings
Positive
+45.3%
Q4 2020
Best reaction
-12.0%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | -8.7% | -16.5% | |
| Q4 2025 | -0.2% | -1.7% | -3.1% | |
| Q3 2025 | +5.2% | +7.6% | +9.8% | |
| Q1 2025 | +5.2% | -3.0% | -23.8% | |
| Q4 2024 | +2.0% | -4.6% | -15.0% | |
| Q3 2024 | -4.7% | -22.5% | -23.6% | |
| Q2 2024 | +6.7% | +3.7% | +5.6% | |
| Q1 2024 | -6.5% | -12.0% | -10.2% | |
| Q4 2023 | +2.7% | +0.9% | -4.5% | |
| Q3 2023 | +2.4% | -0.7% | -4.9% | |
| Q2 2023 | -8.7% | -9.7% | -18.3% | |
| Q1 2023 | +17.2% | +13.0% | +2.9% | |
| Q4 2022 | +4.6% | +7.0% | -9.7% | |
| Q3 2022 | -8.8% | -6.6% | +8.6% | |
| Q2 2022 | -8.5% | -2.8% | -19.1% | |
| Q1 2022 | -4.7% | -13.7% | -12.0% | |
| Q4 2021 | -9.6% | -8.3% | +5.1% | |
| Q3 2021 | -0.7% | -4.8% | -21.5% | |
| Q2 2021 | +5.0% | +5.8% | +30.5% | |
| Q1 2021 | -6.6% | -1.8% | +90.3% | |
| Q4 2020 | +45.3% | +46.2% | +46.5% | |
| Q3 2020 | +20.9% | +7.3% | +1.5% | |
| Q2 2020 | +3.5% | +1.5% | +8.2% | |
| Q1 2020 | -7.9% | -0.8% | -11.7% | |
| Q4 2019 | -0.1% | +0.9% | -22.7% | |
| Q3 2019 | -3.1% | -3.0% | +32.7% | |
| Q2 2019 | +2.4% | -2.2% | -1.3% | |
| Q1 2019 | +2.7% | -1.9% | -16.2% | |
| Q4 2018 | +3.1% | +4.3% | +12.5% | |
| Q3 2018 | +0.6% | -4.1% | -9.8% | |
| Q2 2018 | +2.7% | +8.2% | +3.6% | |
| Q1 2018 | -2.4% | +13.1% | -1.2% | |
| Q4 2017 | +8.0% | +11.6% | +18.1% | |
| Q3 2017 | -9.2% | -8.6% | -34.4% | |
| Q2 2017 | -4.2% | -7.1% | -1.3% | |
| Q1 2017 | +11.2% | +12.2% | +3.2% | |
| Q4 2016 | +1.4% | +5.9% | +3.9% | |
| Q3 2016 | -5.6% | -8.3% | +14.3% | |
| Q2 2016 | +2.8% | +2.3% | -7.9% | |
| Q1 2016 | -12.0% | — | — | |
| Q4 2015 | +1.4% | — | — | |
| Q3 2015 | +10.9% | — | — | |
| Q2 2015 | -1.1% | — | — | |
| Q1 2015 | -8.5% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -6.0% | — | — | |
| Q2 2014 | +12.2% | — | — | |
| Q1 2014 | +1.0% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | +4.7% | — | — | |
| Q2 2013 | -1.6% | — | — | |
| Q1 2013 | +11.9% | — | — | |
| Q4 2012 | +0.6% | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro